Screener / SEC EDGAR /CIK 0001070494 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Pharmaceuticals

Acadia Pharmaceuticals Inc ACAD

We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. 10-K, Item 1

Headquarters
San Diego, CA
CEO
Stephen R. Davis
Next results
around Jan 12, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $1.1B through the costs to a net profit of $391.0M · income statement of the 10-K

10% operating margin
Revenue to Gross profit: $982.5MRevenue to Cost of revenue: $89.0MGross profit to Operating profit: $104.8MGross profit to Operating expenses: $877.7MOperating profit to Net profit: $104.8MOther income to Net profit: $286.2MOperating expenses to R&D: $328.8MOperating expenses to SG&A: $548.9M Revenue: $1.1B REVENUE $1.1B +12% Y/Y Gross profit: $982.5M · 92% margin GROSS PROFIT $982.5M 92% margin Cost of revenue: $89.0M · 8% of revenue COST OF REVENUE $89.0M 8% of revenue Operating profit: $104.8M · 10% margin OPERATING PROFIT $104.8M 10% margin · −55% Y/Y Other income: $286.2M · 27% of revenue OTHER INCOME $286.2M 27% of revenue Operating expenses: $877.7M · 82% of revenue OPERATING EXPENSES $877.7M 82% of revenue Net profit: $391.0M · 36% margin NET PROFIT $391.0M 36% margin · +73% Y/Y R&D: $328.8M · 31% of revenue R&D $328.8M 31% of revenue SG&A: $548.9M · 51% of revenue SG&A $548.9M 51% of revenue
Gross profit $982.5M 92% margin
Operating profit $104.8M 10% margin · −55% Y/Y
Net profit $391.0M 36% margin · +73% Y/Y
The full income statement, year by year

ACAD among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 11.9%, above 57% of 154 peers (their median 10.4%) REVENUE GROWTH 11.9% · above 57% Gross margin: 90.5%, above 95% of 107 peers (their median 63.4%) GROSS MARGIN 90.5% · above 95% Operating margin: 10.2%, above 50% of 138 peers (their median 9.8%) OPERATING MARGIN 10.2% · above 50% Net margin: 30.1%, above 95% of 153 peers (their median 6.7%) NET MARGIN 30.1% · above 95% FCF margin: 6.8%, above 39% of 144 peers (their median 10.1%) FCF MARGIN 6.8% · above 39% Return on capital: 21.3%, above 89% of 89 peers (their median 9.0%) RETURN ON CAPITAL 21.3% · above 89%
ACAD Peer median Below the median

What changed

32 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 26, 2026 against Feb 27, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

2facts worth reading about the other 9 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +23.0% ($98.7M to $121.5M) vs revenue +11.9% ($957.8M to $1.1B), +11.1 pts apart
  • Cash from operations lower than net income
    Cash from operations $109.8M vs net income $391.0M (FY ending Dec 31, 2025)
  • Inventory +21.5% ($91.7M to $111.4M) vs revenue +11.9% ($957.8M to $1.1B), +9.6 pts apart
8 more checks with nothing to note
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Medicare Part D sales rebate accruals
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

32 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.

All 32 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    The process of obtaining regulatory approval of medicinal products in the EU and elsewhere, is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects. We operate in a global economy, and our business depends on a global supply chain for the development, manufacturing, and distribution of our pharmaceutical products,…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    For example, on July 4, 2025, the OBBBA was signed into law, which narrowed access to ACA marketplace exchange enrollment and declined to extend the ACA enhanced advanced premium tax credits that expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance.…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    An expansion in the government’s role in the U.S. healthcare industry may increase existing congressional or governmental agency scrutiny on price increases, such as the ones we have implemented for NUPLAZID, cause general downward pressure on the prices of prescription drug products, lower reimbursements for providers using our…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$517.2M$726.4M$957.8M$1.1B
Net income−$216.0M−$61.3M$226.5M$391.0M
Operating cash flow−$114.0M$16.7M$157.7M$109.8M
Free cash flow−$114.0M$16.7M$157.2M$105.1M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$1.1B ▲ 11.9% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

4 filings in the last 30 days · SEC EDGAR

All filings

About the company

Acadia Pharmaceuticals Inc, San Diego, CA · from the 10-K filed Feb 26, 2026

We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. We have two core franchises in neurological and rare diseases. Our neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP).

Headquarters
San Diego, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 4, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ACAD/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.